Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPI-1005 for Prevention of Chemotherapy Induced Hearing Loss
NCT01451853Phase 2Withdrawn
- Sponsor
- Sound Pharmaceuticals
- Start
- Jun 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ebselen in ototoxicity, hearing loss, tinnitus, sponsored by Sound Pharmaceuticals. Planned start Jun 2026; status: withdrawn.
02
Drugs
ebselen
03
Conditions
ototoxicityhearing losstinnitus
Beyond the preview
Go deeper on NCT01451853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01451853.